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RAS genesAbstract Background: Tumour shrinkage (TS) increases the possibility of resection in meta-
static colorectal cancer (mCRC) and may improve tumour-related symptoms. Here we report
prespeciﬁed secondary response–related end-points and exploratory TS/resection outcomes
for patients with RAS wild-type (WT) tumours (no mutations in KRAS/NRAS exons 2/3/4)
from the PRIME study (NCT00364013).
Methods: PRIME was a randomised phase 3 study comparing ﬁrst-line
panitumumab + FOLFOX4 versus FOLFOX4 in mCRC patients. Tumour response analyses
were conducted to compare response rates and their impact on survival outcomes.
Results: Overall, 505 patients had RAS WT mCRC. More patients receiving
panitumumab + FOLFOX4 versus FOLFOX4 had P30% (59% versus 38%; P < 0.001) or
P20% (72% versus 57%; P < 0.001) TS at week 8 (early TS); consistent TS beneﬁts were
observed over the ﬁrst 40 weeks of treatment. Objective response rate (P = 0.003), duration
1232 J.-Y. Douillard et al. / European Journal of Cancer 51 (2015) 1231–1242of response (P = 0.0027), depth of response (P = 0.0149), progression-free survival (PFS;
P = 0.0015) and overall survival (OS; P = 0.0057) were improved in the
panitumumab +FOLFOX4 group. Both early TS and resection were associated with
improved PFS and OS. 2-year OS rates for patients who did (n = 64) versus did not
(n = 441) undergo resection were 88% versus 40%; 2-year OS rates for patients who did
(n = 45) versus did not (n = 460) undergo complete resection were 96% versus 41%.
Conclusions: Morepatients receiving panitumumab +FOLFOX4versusFOLFOX4hadP30%
orP20% TS at week 8; PFS and OS were also improved with panitumumab +FOLFOX4. The
clinical value of achieving early TS in mCRC warrants further investigation.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Colorectal cancer (CRC) is one of the three most
commonly diagnosed tumour types worldwide, and is
also a leading cause of cancer death [1,2]. Achieving
tumour shrinkage when treating patients with metastatic
CRC (mCRC) is an important goal as it can reduce
tumour burden and increase the possibility of surgical
resection – the only potentially curative intervention
for this group of patients [3,4]. Early tumour shrinkage
can rapidly relieve tumour-related symptoms and iden-
tify patients who are early responders; therefore, attain-
ing responses within the ﬁrst eight weeks of treatment is
an important clinical objective.
Tumour response as deﬁned by Response Evaluation
Criteria In Solid Tumours (RECIST) is a common end-
point in clinical trials, and requires that tumour shrink-
age of at least 30% is conﬁrmed at consecutive visits [5];
however, RECIST does not consider timing of response.
It has been reported that in patients with wild-type (WT)
KRAS mCRC treated with chemotherapy and an epi-
dermal growth factor receptor (EGFR)-targeted mono-
clonal antibody (mAb), early tumour shrinkage (P20%)
at weeks 6–8 predicts improved progression-free survival
(PFS) and overall survival (OS) outcomes [6–8]. A fur-
ther study suggested that tumour shrinkage of 10–30%
at ﬁrst follow-up scan, was a positive prognostic factor
for PFS and OS in mCRC patients treated with
chemotherapy alone [9].
PRIME (NCT00364013) is a randomised, multicen-
tre, phase III trial comparing panitumumab (an
EGFR-targeted mAb) + FOLFOX4 with FOLFOX4
alone in the ﬁrst-line treatment of patients with mCRC
[10]. In PRIME, panitumumab + FOLFOX4 signiﬁ-
cantly improved PFS in patients with KRAS exon 2
WT mCRC compared with FOLFOX4 alone [10,11].
Improved OS was also observed in patients with RAS
WT (KRAS/NRAS exons 2–4 assessed) mCRC receiving
panitumumab + FOLFOX4 versus FOLFOX4 [12].
Using RAS WT data from an exploratory OS analysis
performed whenP80% of patients in PRIME had died,
here we report key prespeciﬁed secondary end-points
related to tumour response (e.g. objective response rate
[ORR], time to response [TTR] and duration of response[DoR]). Some exploratory outcomes related to tumour
shrinkage (e.g. depth of response [DpR]) and resection
status and their impact on longer-term survival out-
comes are also reported.
2. Methods
2.1. Study design and patients
PRIME was a randomised (1:1) phase III study com-
paring the eﬃcacy and safety of ﬁrst-line panitumumab
6.0 mg/kg Q2W + FOLFOX4 versus FOLFOX4 alone
in patients with documented, measurable, unresectable
and previously untreated mCRC [10]. Prior adjuvant 5-
ﬂuorouracil-based therapy was permitted if disease
recurrence occurred >6 months after completion of treat-
ment. No prior EGFR inhibitor and/or oxaliplatin ther-
apy was allowed. Patients were also required to have an
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0–2 and adequate haematological, renal
and hepatic function. Paraﬃn-embedded tumour tissue
also needed to be available for central biomarker testing.
2.2. Analysis population
The present analyses included data from patients with
RAS WT mCRC obtained from an exploratory analysis
conducted whenP80% of patients in PRIME had died.
To determine those patients with RAS WT tumours,
banked tumour samples from patients who had KRAS
exon 2 WT mCRC were tested for prespeciﬁed muta-
tions in NRAS exon 2 (codons 12 and 13), and KRAS
and NRAS exons 3 (codon 61) and 4 (codons 117 and
146). Mutations were also tested for in codon 59 of
KRAS and NRAS exon 3, but these were not prespeci-
ﬁed. The updated exploratory analysis population
reported here included patients with no mutations in
any of the following: KRAS and NRAS exons 2 (codons
12 and 13), 3 (codons 59 and 61) and 4 (codons 117 and
146). For completeness, the number of patients with
BRAF mutations at exon 15 (codon 600) was also
assessed. Mutational analysis was performed using both
Sanger sequencing and SURVEYOR/WAVE labora-
tory-developed tests as described previously [12].
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Tumour size was measured by spiral computed
tomography (CT) scan (magnetic resonance imagery
was optional if clinically indicated and used throughout
the study) at baseline and then every 8 ± 1 weeks until
disease progression (PD), in line with modiﬁed
RECIST [5]. Tumour response was assessed by blinded
central radiology review and central review tumour
response data were included in all analyses.
Measurements were based on the sum of the longest
diameters (mm) of measurable target lesions, as identi-
ﬁed per central radiology review.
Data were analysed for patients with RAS WT
mCRC overall to determine the proportion of patients
achieving P30% or P20% tumour shrinkage by week
8, the ORR and the change in tumour load over time.
Change in tumour load was measured as the mean
(95% conﬁdence interval [CI]) percentage change from
baseline in tumour load (the sum of the longest diame-
ters of all target lesions) over time and the resultant ﬁg-
ures show tumour data at each scheduled visit for
patients overall and in patients with liver-limited disease
(LLD) or non-LLD. Following PD, patients were only
followed up for survival and no further CT scans were
taken and so no further tumour load data were available
for patients after this point. Since RAS WT patients
were selected from the KRAS exon 2 WT subgroup, this
could introduce selection bias. A sensitivity analysis
using propensity scores [13,14] was performed to evalu-
ate potential imbalances in baseline prognostic factors
between treatment groups. The propensity score for
each patient was deﬁned as the probability of being trea-
ted with panitumumab + FOLFOX4 given the patient’s
baseline covariate values. Propensity scores were esti-
mated using a logistic regression model with prespeciﬁed
covariates. The estimated propensity scores were
included as a covariate in the Cox proportional hazard
model for the PFS and OS analyses.
DpR was calculated as the percentage change from
baseline to nadir in patients who had tumour shrinkage.
In patients with tumour growth or no change in tumour
size, DpR was deﬁned as the percentage change from
baseline to PD if the patient subsequently progressed,
or as ‘missing’ if the patient did not progress. For
patients with a conﬁrmed OR of a complete (CR) or
partial response (PR), DoR was calculated as the time
from ﬁrst CR or PR (subsequently conﬁrmed no less
than 4 weeks) to ﬁrst observed PD per modiﬁed
RECIST [5]. Patients not meeting these criteria by the
analysis data cut-oﬀ date had their DoR time censored
at their last evaluable disease assessment date. TTR
was calculated as the time from randomisation date to
ﬁrst CR or PR (subsequently conﬁrmed no less than
4 weeks); patients with a best response of stable disease
(SD) at their last evaluable assessment date werecensored at this date and patients with a best response
of PD while on study were censored at the maximum
observed time to a ﬁrst conﬁrmed response among all
responders. Rates of metastasectomy and complete
resection, median PFS/OS and 6-month PFS and 2-year
OS rates were determined. PFS was calculated as the
time from randomisation date to date of PD per modi-
ﬁed RECIST [5] or death (whichever occurred ﬁrst).
Patients not meeting these criteria at the time of the
analysis data cut-oﬀ date had their PFS time censored
at the last evaluable disease assessment date. Similarly,
OS was calculated as the time from randomisation to
date of death. Patients who had not died by the time
of the analysis data cut-oﬀ date had their time of death
censored at the last contact date on which they were
known to be alive. Top-line eﬃcacy data were also anal-
ysed for the subgroups of RAS WT patients with LLD
and non-LLD.
All data were summarised descriptively and tested for
signiﬁcance between treatment groups using Cox’s pro-
portional hazards models (and Wald tests to generate
P-values), Fisher’s exact test and Wilcoxon two-sample
tests, where appropriate.
2.3.1. Impact of tumour shrinkage and resection on
outcome
Median PFS and OS were also calculated by week 8
tumour shrinkage status (<30% or P30% and <20%
orP20%). Binary coeﬃcients (u, phi) [15], for the asso-
ciation between achieving P30% or P20% tumour
shrinkage at week 8 (yes/no) and PFS at 6 months
(yes/no) and OS at 2 years (yes/no), were calculated.
Patients who were censored before 6 months were
assumed to have progressed at this point, likewise,
patients who were censored before 2 years were assumed
to have died. Phi coeﬃcients range from approximately
1 to +1, with negative values indicating inverse corre-
lations, positive values indicating direct correlations and
zero indicating no relationship between variables.
Waterfall plots of individual patient tumour shrink-
age at week 8 (overall population) indicating those
who were progression-free at 6 months or alive at
2 years, provided a visual determination as to whether
tumour shrinkage is an appropriate surrogate for these
outcomes. Multivariate analyses were performed to
explore the prognostic relevance of various baseline
and non-baseline covariates on PFS and OS.
Treatment, baseline LLD, baseline ECOG score (0 or
1, 2), region (Australia and Canada, Western Europe,
Rest of World), baseline lactate dehydrogenase (LDH)
levels (P1.5  upper limit of normal [ULN] or not),
tumour shrinkage at week 8 (P30% andP20% cut-oﬀs)
and resection status (time-dependent variable) were
included in the Cox proportional hazard model. A step-
wise approach was used where a signiﬁcance level of
10% was required for a covariate to enter or be removed
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explored. To investigate the potential interaction eﬀects
of tumour shrinkage and resection status on outcomes, a
multivariate Cox proportional hazards model was used
with achievement of tumour shrinkage at week 8
(P30% and P20% cut-oﬀs), treatment and resection
status included as covariates.
An exploratory (descriptive) analysis of outcomes for
resected and non-resected patients was also performed.
Median PFS was estimated in those patients undergoing
any resection or liver/lung surgery, without censoring
them at the time of the surgical procedure. Median OS
and 2-year OS rates were also calculated by resection
status (no resection, any resection or complete resec-
tion). Median relapse-free survival (RFS) following
resection was determined for on-treatment patients
(patients without PD) who underwent a complete resec-
tion. RFS was deﬁned as the time interval between date
of complete resection and date of PD or death (which-
ever occurred ﬁrst), or date of censoring (patients had
their RFS time censored at their last evaluable disease
assessment date).
3. Results
3.1. Patients
Of the 1183 patients with previously untreated/unre-
sectable mCRC randomised in PRIME, 505 patients
had RAS WT mCRC (panitumumab + FOLFOX4
n = 253; FOLFOX4 n = 252) and were included in the
updated exploratory analysis population. This popula-
tion excluded seven patients with mutations in KRAS
or NRAS exon 3 codon 59 who were identiﬁed in the
exploratory analysis. Of these, 440 patients had available
tumour shrinkage data at week 8 (panitumum
ab + FOLFOX4 n = 219; FOLFOX4 n = 221) and were
included in the tumour shrinkage analyses. Sixty-ﬁve
patients (panitumumab + FOLFOX4 n = 34; FOLFO
X4 n = 31) had missing tumour shrinkage data at base-
line and/or week 8 due to PD/death (n = 6; n = 6), ended
treatment due adverse event (n = 2; n = 0), consent with-
drawal (n = 1; n = 4), or protocol deviation (n = 0;
n = 1), respectively. The reason for missing scans was
recorded as ‘other’ for 25 and 20 patients in the
panitumumab + FOLFOX4 and FOLFOX4 groups,
respectively. The most common ‘other’ reasons for a
missing scan were no week 8 assessment done/scan per-
formed outside of the week 8 window (n = 15; n = 9)
and patient not evaluable for central tumour response
analysis set (n = 5; n = 6). The central tumour response
analysis set included 494 patients (panitum
umab + FOLFOX4 n = 248; FOLFOX4 n = 246).
Similar numbers of patients in each treatment group
had BRAF mutations (panitumumab + FOLFOX4
n = 24; FOLFOX4 n = 29).Baseline demographics and characteristics were gen-
erally well-balanced between treatment groups; overall,
most patients (94%) had an ECOG performance status
of 0/1 and had a primary diagnosis of colon cancer
(65%) (Table 1). Overall 89 patients had both RAS
WT mCRC and LLD and 416 patients had non-LLD
(Table 1). Baseline demographics and characteristics
were well balanced between treatments with respect to
sex, age and metastatic sites in both LLD and non-
LLD populations. Proportionally more LLD patients
in the panitumumab + FOLFOX4 group had primary
colon cancer compared with the FOLFOX4 group
(77% versus 59%, respectively).3.2. Eﬃcacy
3.2.1. Tumour response
In 494 evaluable RASWT patients, the ORR was sig-
niﬁcantly higher in the panitumumab + FOLFOX4 ver-
sus FOLFOX4 arm (60% versus 47%; P = 0.003)
(Table 2); complete response rates were <1% in each
arm, partial response rates were 60% versus 46%, SD
rates were 27% versus 37%, and PD rates were 7% versus
12%, respectively. Median DoR was signiﬁcantly longer
(11.8 versus 8.4 months; P = 0.0027) and median TTR
was signiﬁcantly shorter (3.4 months versus not evalu-
able; P = 0.0006) in the panitumumab + FOLFOX4
group (Table 2). Signiﬁcantly more patients in the
panitumumab + FOLFOX4 group versus the
FOLFOX4 group had P30% (59% versus 38%;
P < 0.001) or P20% (72% versus 57%; P < 0.001)
tumour shrinkage at week 8 (early tumour shrinkage).
In general, similar improvements in tumour responses
were also seen in patients with LLD and non-LLD trea-
ted with panitumumab, although diﬀerences were not
always statistically signiﬁcant (Table 2).3.2.2. Resection rates
Rates of any resection (14% versus 12%) and com-
plete resection (10% versus 8%) were numerically higher
in the overall population for patients treated with
panitumumab + FOLFOX4 versus FOLFOX4
(Table 2).
In patients with LLD versus non-LLD, overall (30%
versus 9%) and complete (25% versus 6%) resection rates
were higher in the panitumumab arm versus FOLFOX4
alone; in 89 patients with LLD, complete resection rates
were higher with panitumumab + FOLFOX4 versus
FOLFOX4 alone (31% versus 17%).3.2.3. Progression-free and overall survival
Of the 440 patients with both baseline and week 8
tumour measurements, 393 patients progressed or died
on study, therefore, 47 were censored in the PFS analyses
(FOLFOX4 n = 16 [7%]; panitumumab + FOLFOX4
Table 1
Baseline demographics and disease characteristics (RAS wild-type patients).
Overall LLD non-LLD
Panitumumab + FOLFOX4
(n = 253)
FOLFOX4
(n = 252)
Panitumumab + FOLFOX4
(n = 48)
FOLFOX4
(n = 41)
Panitumumab + FOLFOX4
(n = 205)
FOLFOX4
(n = 211)
Sex – n (%) male 170 (67) 158 (63) 29 (60) 23 (56) 141 (69) 135 (64)
Median age (range) – years 61 (27, 81) 61 (24, 82) 60 (41, 77) 58 (27, 82) 61 (27, 81) 61 (24, 80)
ECOG score – n (%)
0/1 238 (94) 235 (93) 46 (96) 40 (98) 192 (94) 195 (92)
2 15 (6) 17 (7) 2 (4) 1 (2) 13 (6) 16 (8)
Primary diagnosis – n (%)
Colon cancer 165 (65) 164 (65) 37 (77) 24 (59) 128 (62) 140 (66)
Rectal cancer 88 (35) 88 (35) 11 (23) 17 (41) 77 (38) 71 (34)
Sites of metastases – n (%)
Liver only 48 (19) 41 (16) 48 (100) 41 (100) - -
Lung only 0 (0) 0 (0) – – 0 (0) 0 (0)
Liver + lung only 2 (1) 2 (1) – – 2 (1) 2 (1)
Liver + lung + other 14 (6) 17 (7) – – 14 (7) 17 (8)
Liver + any except lung 153 (60) 153 (61) – – 153 (75) 153 (73)
Lung + any except liver 5 (2) 10 (4) 5 (2) 10 (5)
Other only 31 (12) 29 (12) – – 31 (15) 29 (14)
Number of metastatic organs – n (%)
>3 46 (18) 43 (17) 0 (0) 0 (0) 46 (22) 43 (20)
63 206 (81) 209 (83) 48 (100) 41 (100) 158 (77) 168 (80)
Prior adjuvant chemotherapy – n (%)
Yes 42 (17) 38 (15) 4 (8) 3 (7) 38 (19) 35 (17)
No 211 (83) 214 (85) 44 (92) 38 (93) 167 (81) 176 (83)
ECOG, Eastern Cooperative Oncology Group; LLD, liver-limited disease; non-LLD, non-liver-limited disease.
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Table 2
Tumour shrinkage, response and resection outcomes (RAS wild-type patients).
Overall LLD non-LLD
Panitumumab + FOLFOX4
(n = 253)
FOLFOX4
(n = 252)
Panitumumab + FOLFOX4
(n = 48)
FOLFOX4
(n = 41)
Panitumumab + FOLFOX4
(n = 205)
FOLFOX4
(n = 211)
Tumour shrinkage data at week 8a –
n (%)
219 (87) 221 (88) 43 (90) 35 (85) 176 (86) 186 (88)
P30% shrinkage at week 8a – n (%) 130 (59) 83 (38) 34 (79) 18 (51) 96 (55) 65 (35)
% diﬀerence (95% CI) 21.8 (12.7, 30.9) 27.6 (7.1, 48.2) 19.6 (9.5, 29.7)
P-valueb <0.001 0.015 <0.001
P20% shrinkage at week 8a – n (%) 158 (72) 125 (57) 38 (88) 27 (77) 120 (68) 98 (53)
% diﬀerence (95% CI) 15.6 (6.8, 24.4) 11.2 (5.7, 28.1) 15.5 (5.6, 25.4)
P-valueb <0.001 0.229 0.003
Objective responsec – n (%) 150 (60) 115 (47) 38 (81) 27 (66) 112 (56) 88 (43)
% diﬀerence (95% CI) 13.7 (5.0, 22.4) 15.0 (3.4, 33.4) 12.8 (3.1, 22.4)
P-valueb 0.003 0.146 0.013
Any resection – n (%) 35 (14) 29 (12) 16 (33) 11 (27) 19 (9) 18 (9)
% diﬀerence (95% CI) 2.3 (3.5, 8.1) 6.5 (12.5, 25.5) 0.7 (4.7, 6.2)
P-valueb 0.504 0.644 0.864
Complete resection – n (%) 26 (10) 19 (8) 15 (31) 7 (17) 11 (5) 12 (6)
% diﬀerence (95% CI) 2.7 (2.2, 7.7) 14.2 (3.3, 31.6) 0.3 (4.7, 4.1)
P-valueb 0.349 0.145 1.000
Median TTRc – months 3.4 NE 1.8 3.2 3.7 NE
HRd (95% CI) 0.65 (0.51, 0.83) 0.55 (0.33, 0.90) 0.68 (0.51, 0.90)
P-valuec 0.0006 0.0171 0.0063
Median DoRc – months 11.8 8.4 15.0 8.8 11.1 8.4
HR (95% CI) 0.63 (0.46, 0.85) 0.60 (0.33, 1.09) 0.62 (0.44, 0.89)
P-valuee 0.0027 0.0938 0.0101
Median PFS – months 11.1 8.7 11.3 9.9 11.1 8.0
HR (95% CI) 0.74 (0.61, 0.89) 0.75 (0.48, 1.19) 0.73 (0.60, 0.90)
P-valuee 0.0015 0.2223 0.0027
Median OS – months 26.0 20.2 40.7 33.4 23.8 18.4
HR (95% CI) 0.76 (0.63, 0.92) 0.71 (0.43, 1.16) 0.78 (0.63, 0.96)
P-valuee 0.0057 0.1737 0.0185
CI, conﬁdence interval; DoR, duration of response; HR, hazard ratio; LLD, liver-limited disease; NE, not evaluable; non-LLD, non-liver-limited disease; OS, overall survival; PFS, progression-free
survival; TTR, time to response.
a For patients assessed at baseline and week 8 only – if patients not assessed at both baseline and week 8 are assumed to not have tumour shrinkage, the overall values are 130 (51%) and 83 (33%);
P < 0.001, the LLD values are 34 (71%) and 18 (44%); P = 0.017 and the non-LLD values are 96 (47%) and 65 (31%); P < 0.001, for panitumumab + FOLFOX4 and FOLFOX4 alone, respectively.
b Descriptive P-value (Fisher exact test).
c Data were based on the central tumour response analysis set (overall panitumumab + FOLFOX4 n = 248; FOLFOX4 n = 246).
d HR is for FOLFOX4 versus panitumumab + FOLFOX4 and favours FOLFOX4.
e Descriptive P-value (Wald test).
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77 were censored in the OS analyses (FOLFOX4 n = 50
[23%]; panitumum ab + FOLFOX4 n = 27 [12%]).
Overall, patients in the panitumumab + FOLFOX4
group had signiﬁcantly longer median PFS (11.1 versus
8.7 months; P = 0.0015) and OS (26.0 versus
20.2 months; P = 0.0057) than those in the FOLFOX4
group (Table 2). After controlling for the eﬀects of covari-
ates, PFS (but notOS) remained signiﬁcantly improved in
the panitumumab arm (Supplementary Tables S1 and
S2). Signiﬁcant PFS and OS beneﬁts were seen in patients
with non-LLD receiving panitumumab; improvements
were also seen in patients with LLD, but did not reach sta-
tistical signiﬁcance likely because of the sample size
(Table 2). Overall, 6-month PFS rates and 2-yearOS rates
for patients receiving panitumumab + FOLFOX4 versus
FOLFOX4 alone were 71% versus 60% and 50% versus
41%, respectively. Six-month PFS and 2-year OS rates
for patients with LLDwere 85% versus 71% and 65% ver-
sus 61% for patients receiving panitumum
ab + FOLFOX4 versus FOLFOX4 alone; corresponding
rates for non-LLD patients were 67% versus 58% and
47% versus 37%, respectively.3.2.4. Tumour load over time and impact of tumour
shrinkage on outcome
Over the ﬁrst 40 weeks of study treatment,
panitumumab + FOLFOX4 oﬀered a consistent beneﬁt
over FOLFOX4 alone in terms of mean percentage
change in tumour load from baseline (Fig. 1). The
results adjusted for propensity score estimates were con-
sistent with the unadjusted results (data not shown).
Similar tumour shrinkage beneﬁts were seen in LLD
and non-LLD patients (Supplementary Figs. S1A and
S1B, respectively). Median percentage DpR was also
higher for panitumumab + FOLFOX4 versus
FOLFOX4 alone (54% versus 46%, P = 0.0149; Fig. 1).
Amongst those achievingP30% tumour shrinkage at
week 8, patients receiving panitumumab + FOLFOX4
showed signiﬁcantly longer median PFS (P = 0.0194)
and numerically longer median OS (P = 0.3082) than
those receiving FOLFOX4 alone (Table 3). PFS and
OS outcomes were similar between treatments for those
patients who achieved <30% or <20% tumour shrinkage
at week 8. Irrespective of treatment received, median
PFS and OS values were signiﬁcantly longer in patients
who achieved P30% or P20% tumour shrinkage at
week 8, than in those patients who did not (Table 3).
The Waterfall plots of PFS and OS, by week 8 tumour
shrinkage in the panitumumab + FOLFOX4 group,
suggested slight improvements in survival outcomes
among patients achieving the greatest shrinkage
(Supplementary Fig. S2). Irrespective of treatment
received, prognosis was poorer for patients with on-
treatment tumour growth at week 8 (n = 42), with only12 (29%) and 6 (14%) patients PD-free at 6 months or
alive at 2 years, respectively.
Although in general, proportionally more patients
achieving either tumour shrinkage criterion at week 8
survived PD-free at 6 months or were alive at 2 years
than those who did not, phi coeﬃcients were poor
between P30% or P20% shrinkage at week 8 and 6-
month PFS and 2-year OS outcomes (Table 3 and
Supplementary Table S3). Overall, 13 patients were cen-
sored before 6 months and seven patients were censored
before 2 years and so for the purpose of these analyses
were considered to have progressed or died at 6 months
and 2 years, respectively.
In the multivariate analyses of PFS, the covariates
found to be signiﬁcant were achieving tumour shrinkage
at week 8 (P20% andP30% cut-oﬀs), treatment, resec-
tion and baseline ECOG score (no interactions were sig-
niﬁcant). In the multivariate analyses of OS using
P30% tumour shrinkage as a criterion, the covariates
found to be signiﬁcant were achieving tumour shrinkage
at week 8, treatment, resection, baseline ECOG score,
baseline LDH levelP1.5  ULN, region and the interac-
tion between region and achieving tumour shrinkage at
week 8 (Supplementary Table S1). However, inmultivari-
ate analyses ofOS usingP20% tumour shrinkage as a cri-
terion, region was not signiﬁcant and the only signiﬁcant
interaction was between baseline LDH levels
P1.5  ULN and achieving tumour shrinkage at week
8 (Supplementary Table S2). Achievement of tumour
shrinkage at week 8 was associated with improved PFS/
OS versus no tumour shrinkage after adjusting for treat-
ment and other signiﬁcant covariates (Supplementary
Tables). LLD was not found to be signiﬁcant in the mul-
tivariate analyses and so was not kept in the ﬁnal models
for PFS or OS.3.2.5. Impact of resection on outcome
Overall, median PFS was 21.6 versus 13.8 months in
all patients receiving panitumumab + FOLFOX4 versus
FOLFOX4 who underwent any resection (hazard ratio
[HR]: 0.68 [95% CI: 0.38, 1.25]; P = 0.2151) (Fig. 2A).
PFS was also improved in patients receiving
panitumumab + FOLFOX4 who did not undergo resec-
tion (P = 0.0060) (Fig. 2A). In patients speciﬁcally
undergoing liver/lung resections (n = 56), PFS was
numerically longer in those receiving
panitumumab + FOLFOX4 versus FOLFOX4 alone
(P = 0.2301). For the 38 patients who were on treatment
and underwent complete resection before PD or death,
median RFS following resection was 22.0 versus
12.4 months for patients receiving panitumumab + FO
LFOX4 (n = 21) versus FOLFOX4 (n = 17), respectively
(HR: 0.66 [95% CI: 0.29, 1.54; P = 0.3419). Results of the
time-dependent Cox proportional hazards analyses
showed that resected patients had improved PFS and
OS versus non-resected patients, after controlling for
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Table 3
Summary table of survival outcomes by tumour shrinkage at week 8 (overall; RAS wild-type patients) n (%).
Tumour shrinkage at week 8 Panitumumab + FOLFOX4 FOLFOX4 alone
<30% P30% <30% P30%
na (%) 89 (41) 130 (59) 138 (62) 83 (38)
Median PFS 9.3 14.9 7.0 10.9
(95% CI) – months (6.7, 10.7) (12.8, 18.6) (5.7, 7.8) (9.3, 11.7)
HR (95% CI) 0.56 (0.42, 0.76) 0.62 (0.47, 0.83)
P-value 0.0001 0.0014
Phi coeﬃcientb 0.30
Median OS 18.2 34.5 16.0 30.7
(95% CI) – months (14.2, 22.5) (29.8, 40.7) (14.2, 18.8) (23.6, 36.2)
HR (95% CI) 0.52 (0.38, 0.70) 0.46 (0.34, 0.63)
P-value <0.0001 <0.0001
Phi coeﬃcientc 0.33
<20% P20% <20% P20%
61 (28) 158 (72) 96 (43) 125 (57)
Median PFS 6.7 13.6 6.1 9.9
(95% CI) – months (5.4, 9.9) (12.0, 15.7) (5.3, 8.0) (8.0, 11.1)
HR (95% CI) 0.62 (0.45, 0.85) 0.67 (0.50, 0.88)
P-value 0.0031 0.0040
Phi coeﬃcientb 0.31
Median OS 12.6 32.5 15.2 26.0
(95% CI) – months (9.3, 18.2) (28.3, 37.6) (11.4, 17.2) (22.1, 31.3)
HR (95% CI) 0.47 (0.34, 0.65) 0.50 (0.37, 0.66)
P-value <0.0001 <0.0001
Phi coeﬃcientc 0.34
CI, conﬁdence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
a Includes patients with baseline and week 8 tumour shrinkage data only.
b Assessing the overall relationship between week 8 tumour shrinkage and PFS at 6 months.
c Assessing the overall relationship between week 8 tumour shrinkage and OS at 2 years.
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Interaction eﬀects of tumour shrinkage and resection
were investigated through multivariate analyses of PFSand OS; HRs indicated that tumour shrinkage was asso-
ciated with improved PFS andOS in patients who did not
undergo resection (Supplementary Tables S4 and S5).
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57.4 versus 54.5 months (HR: 0.66 [95% CI: 0.32, 1.35];
P = 0.2534) for panitumumab + FOLFOX4 versus
FOLFOX4 alone, respectively (Fig. 2B). OS was longer
in patients who did not undergo resection and received
panitumumab + FOLFOX4 versus FOLFOX4
(P = 0.0186) (Fig. 2B). Overall, 2-year OS rates for
patients who did (n = 64) versus did not (n = 441)
undergo any resection were 88% versus 40%, respec-
tively; corresponding rates for patients who did
(n = 45) versus did not (n = 460) undergo a complete
resection were 96% versus 41%, respectively. The timing
of resection (<cycle 12 versusPcycle 12) did not appear
to signiﬁcantly impact PFS or OS outcome (data not
shown).
4. Discussion
In these analyses of patients with RAS WT mCRC,
the ORR was higher in the panitumu
mab + FOLFOX4 group versus FOLFOX4 alone, both
for the overall population and for those with LLD, con-
sistent with the previous ﬁndings [10,11]. Furthermore,
signiﬁcantly more patients in the panitumu
mab + FOLFOX4 versus FOLFOX4 group experienced
P30% tumour shrinkage by week 8, suggesting that
panitumumab is associated with rapid responses in a
subgroup of patients with RAS WT tumours.
Importantly, this could enable resection in at least some
patients with initially unresectable metastases, and
thereby improve their chance of long-term survival,
and could also improve tumour symptoms in patients
whose disease remains unresectable during treatment.
TTR was signiﬁcantly quicker with panitumu
mab + FOLFOX4 versus FOLFOX4 and DoR was also
longer in this group. Interestingly, a consistent beneﬁt in
terms of change in tumour load was also observed over
the ﬁrst 40 weeks of treatment for the panitu
mumab + FOLFOX4 group. In line with this, median
DpR was higher for panitumumab + FOLFOX4 versus
FOLFOX4 alone. The median DpR in the present study
for panitumumab + FOLFOX4 (54%) is perhaps
slightly higher than that recently noted for ﬁrst-line
cetuximab + FOLFIRI (48%) or bevacizumab + FOL
FIRI (33%) treatment in the FIRE-3 study [16], perhaps
due to the diﬀerence in chemotherapy backbone.
Resection rates in the present study were not signiﬁ-
cantly diﬀerent in the panitumumab + FOLFOX4 ver-
sus FOLFOX4 group and were comparatively low in
patients with non-LLD. However, resection of non-liver
metastases was not standard practice at the time of this
study. After controlling for other covariates resected
patients had improved PFS and OS versus non-resected
patients in the time-dependent Cox proportional haz-
ards model. Multivariate analyses of PFS and OS were
conducted to determine whether improved outcomes inpatients with tumour shrinkage were associated with
resection in these patients. While achieving resection
was associated with clear PFS and OS beneﬁts, tumour
shrinkage was associated with improved PFS and OS in
patients who did not undergo resection. RFS was also
non-signiﬁcantly improved in patients undergoing com-
plete resection, however, this analysis is limited by the
fact that it only includes a small number of patients
and also only includes a proportion of patients undergo-
ing complete resection, as data beyond ﬁrst PD were not
collected in PRIME.
While our analyses show that eitherP30% orP20%
tumour shrinkage at week 8 is associated with improved
PFS and OS at a population level, the phi coeﬃcients
suggest that these end-points are not strong surrogates
for PFS or OS. However, this is conservative measure,
and, therefore, may underestimate beneﬁts. A further
limitation of these analyses is the potential for bias, as
patients with early PD or death were excluded from
the analysis because they had no tumour shrinkage data
available at week 8. Nonetheless, a sensitivity analysis
performed where patients with missing baseline or week
8 data were assumed not to have achieved P30%
tumour shrinkage produced similar results, suggesting
that the ﬁndings are reliable. Interestingly, results of
the time-dependent Cox analyses showed that presence
of tumour shrinkage at week 8 (P30% or P20%) was
prognostic for PFS and OS outcomes. The signiﬁcant
interaction between baseline LDH levels P1.5  ULN
and achieving tumour shrinkage at week 8 may be clin-
ically relevant and should be investigated further. The
reason for the interaction between region and tumour
shrinkage in the analyses using the P30% tumour
shrinkage cut-oﬀ is unclear. Previous studies have also
shown early tumour shrinkage to be associated with
improved PFS and OS outcomes in patients with
mCRC [6–9,16], however, there is currently no standard
way of measuring this outcome. Studies to date have
used shrinkage cut-oﬀs (versus baseline) of P20% [6–
8,16] and 10–30% [9], measured at time points of six
[8,16], seven [7] and eight [6] weeks, depending on the
timing of the ﬁrst post-treatment scan. In the current
study a shrinkage cut-oﬀ corresponding to a RECIST
response (P30%) was chosen, although top-line data
for theP20% cut-oﬀ are also reported for completeness.
Shrinkage was assessed at week 8 as this was the time of
the ﬁrst post-treatment scan in PRIME. Other methods
of assessing tumour shrinkage have also been reported
in the literature. For example, Giessen et al. proposed
quantitative models for the estimation of individual
PFS and OS outcomes based on individual tumour
shrinkage proﬁles [7], and also suggested that a more
precise prediction of individual outcomes could be made
using a volume-based algorithm rather than RECIST
[17]. However, this method is not yet validated and it
may not be realistic to use tumour volume-based
J.-Y. Douillard et al. / European Journal of Cancer 51 (2015) 1231–1242 1241methods in daily practice. A subsequent analysis by
Mansmann et al. suggested that DpR was prognostic
for post-PD survival time in mCRC, when using both
RECIST and volume-based approaches [18]. DpR was
also highly correlated with OS in the FIRE-3 study
[16]. In contrast, in a retrospective analysis of beva-
cizumab data, objective response did not predict the
magnitude of PFS or OS beneﬁt, and the authors con-
cluded that, in mCRC, tumour response was not neces-
sarily needed for an individual patient to beneﬁt from
therapy [19].
While we support the importance of tumour response
in improving the potential for tumour resection and
thereby potentially positively inﬂuencing patient sur-
vival [3,4], our results suggest that other factors are also
important in determining an individual patient’s long-
term outcome. In addition to any impact of post-PD
treatment [20–22], many other possible factors with the
potential to aﬀect PFS and OS in the intervening period
between week 8 and a PD or death are acknowledged,
but methodologically not accounted for in the Cox
regression analyses [23]. These include, but are not lim-
ited to, a patient’s existing or new comorbidities, the
subsequent resection of lesions, the development of
new lesions (this is a major factor impacting OS), and
the diﬀerential impact of treatment on non-target lesions
[24]. Furthermore, diﬀerences in tumour measurements
can occur when lesions are assessed by diﬀerent radiolo-
gists, which may impact on the reporting of objective
responses in clinical trials [25]. For all of these reasons,
we believe that a decision whether to continue or discon-
tinue therapy should not be based solely on the basis of
the presence or absence of early tumour shrinkage.
Instead, treatment decisions should be based on the mul-
tidisciplinary team’s clinical judgement after an overall
assessment of the patient’s situation, including their dis-
ease and comorbidity status.
5. Conclusions
In PRIME, more patients receiving
panitumumab + FOLFOX4 versus FOLFOX4 alone
had tumour shrinkage at week 8. More than half of
the patients in this treatment group achieved P30%
tumour shrinkage and nearly three-quarters achieved
P20% shrinkage at this time point. Patients receiving
panitumumab + FOLFOX4 versus FOLFOX4 alone
also had longer PFS and OS, and for the population
as a whole, early tumour shrinkage appeared to be asso-
ciated with improved PFS and OS irrespective of treat-
ment received. Although an interesting observation, in
this study, P30% or P20% tumour shrinkage at week
8 were not predictive of outcome in individual patients
and so are not unequivocally utilisable in guiding treat-
ment decisions for all patients. Nonetheless, we expect
that some patients will beneﬁt from early tumour
shrinkage, either through alleviation of symptoms orthrough their tumours converting from unresectable to
resectable status.
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